Global Biomarker Market Research and Forecast 2018-2023
The key factors contributing to the growth of the global biomarker market include high prevalence of chronic diseases, rising adoption of biomarker for diagnostic applications, high government funding for cancer research and clinical trials, increasing application in drug discovery and development. High investments cost and low-cost benefit ratio and technical issue such sample collection and storage are restraining the growth of the biomarker market. however, introduction of new technologies such as digital biomarker and rising adoption in personalized medicine are creating opportunities for the market.
The global biomarker market is segmented on the basis of type, application, disease and end user. On the basis of type, the market is bifurcated into genomic and protein biomarker. The application segment is bifurcated into drug discovery and development, diagnostic, prognostic, predictive and others (risk assessment). The disease segment is bifurcated into cancer biomarker, cardiac biomarker, renal biomarker, central nervous system disease and others (NASH). The end user segment is bifurcated into hospitals, diagnostic centre and research institute.
The global biomarker market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. North America holds a dominant position in the global biomarker market, followed by Europe. This is mainly due to high prevalence of chronic diseases and rising adoption of biomarker technology for diagnostic applications significantly contributing towards the market growth in the region. The Asia pacific is projected to exhibit the fastest growth in the global biomarker market over the forecast period. This is due to high government funding for cancer research and clinical trials and high prevalence of chronic disease.
Some of the key players operating in the global biomarker market are Abbott laboratories, Qiagen NV, PerkinElmer Inc., Bio-Rad laboratories and others. In order to sustain in the competitive market, these players adopt various strategies such as Acquisitions, mergers, expansions, joint ventures and product development for the growth of the market.
Research Methodology
The market study of biomarker market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Market Segmentation:
Global biomarker market is segmented on the basis of regional outlook and following segments:
1. Global Biomarker Market Research and Analysis, By Type
2. Global Biomarker Market Research and Analysis, By Application
3. Global Biomarker Market Research and Analysis, By Disease
4. Global Biomarker Market Research and Analysis, By End User
5. Global Biomarker Market Research and Analysis, By Region
THE REPORT COVERS:
The global biomarker market is segmented on the basis of type, application, disease and end user. On the basis of type, the market is bifurcated into genomic and protein biomarker. The application segment is bifurcated into drug discovery and development, diagnostic, prognostic, predictive and others (risk assessment). The disease segment is bifurcated into cancer biomarker, cardiac biomarker, renal biomarker, central nervous system disease and others (NASH). The end user segment is bifurcated into hospitals, diagnostic centre and research institute.
The global biomarker market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. North America holds a dominant position in the global biomarker market, followed by Europe. This is mainly due to high prevalence of chronic diseases and rising adoption of biomarker technology for diagnostic applications significantly contributing towards the market growth in the region. The Asia pacific is projected to exhibit the fastest growth in the global biomarker market over the forecast period. This is due to high government funding for cancer research and clinical trials and high prevalence of chronic disease.
Some of the key players operating in the global biomarker market are Abbott laboratories, Qiagen NV, PerkinElmer Inc., Bio-Rad laboratories and others. In order to sustain in the competitive market, these players adopt various strategies such as Acquisitions, mergers, expansions, joint ventures and product development for the growth of the market.
Research Methodology
The market study of biomarker market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
- Financial reports of companies involved in the market
- Authentic Public Databases such as WHO, American Cancer Society and others
- Whitepapers, research-papers, and news blogs
- Company websites and their product catalogue
Market Segmentation:
Global biomarker market is segmented on the basis of regional outlook and following segments:
1. Global Biomarker Market Research and Analysis, By Type
2. Global Biomarker Market Research and Analysis, By Application
3. Global Biomarker Market Research and Analysis, By Disease
4. Global Biomarker Market Research and Analysis, By End User
5. Global Biomarker Market Research and Analysis, By Region
THE REPORT COVERS:
- Comprehensive research methodology of global biomarker market.
- This report also includes detailed and extensive market overview with key analyst insights.
- Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global biomarker market.
- Insights about market determinants which are stimulating the global biomarker market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
CHAPTER 1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
CHAPTER 2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHT & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1.1. UNITED STATES
2.3.1.2. EUROPEAN UNION
2.3.1.3. CHINA
2.3.1.4. INDIA
CHAPTER 3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. HIGH PREVALENCE OF CHRONIC DISEASES
3.1.2. RISING ADOPTION OF BIOMARKER FOR DIAGNOSTIC APPLICATIONS
3.1.3. HIGH GOVERNMENT FUNDING FOR CANCER RESEARCH AND CLINICAL TRIALS
3.1.4. INCREASING APPLICATION IN DRUG DISCOVERY AND DEVELOPMENT
3.2. RESTRAINT
3.2.1. HIGH INVESTMENTS COST AND LOW-COST BENEFIT RATIO
3.2.2. TECHNICAL ISSUE SUCH SAMPLE COLLECTION AND STORAGE
3.3. OPPORTUNITY
3.3.1. INTRODUCTION OF NEW TECHNOLOGIES SUCH AS DIGITAL BIOMARKER
3.3.2. RISING ADOPTION IN PERSONALIZED MEDICINE
CHAPTER 4. MARKET SEGMENTATION
4.1. GLOBAL BIOMARKER MARKET, BY TYPE
4.1.1. GENOMIC BIOMARKER
4.1.2. PROTEIN BIOMARKER
4.2. GLOBAL BIOMARKER MARKET, BY APPLICATION
4.2.1. DRUG DISCOVERY AND DEVELOPMENT
4.2.2. DIAGNOSTIC
4.2.3. PROGNOSTIC
4.2.4. PREDICTIVE
4.2.5. OTHERS (RISK ASSESSMENT)
4.3. GLOBAL BIOMARKER MARKET, BY DISEASE
4.3.1. CANCER BIOMARKER
4.3.2. CARDIAC BIOMARKER
4.3.3. RENAL BIOMARKER
4.3.4. CENTRAL NERVOUS SYSTEM DISEASE
4.3.5. OTHERS(NASH)
4.1. GLOBAL BIOMARKER MARKET, BY END USER
4.1.1. HOSPITALS
4.1.2. DIAGNOSTIC CENTRE
4.1.3. RESEARCH INSTITUTE
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1. KEY MARKET STRATEGIES
5.2. KEY COMPANY ANALYSIS
CHAPTER 6. REGIONAL ANALYSIS
6.1. NORTH AMERICAN
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. U.K
6.2.2. GERMANY
6.2.3. ITALY
6.2.4. SPAIN
6.2.5. FRANCE
6.2.6. ROE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. ROAPAC
6.4. REST OF THE WORLD
CHAPTER 7. COMPANY PROFILES
7.1. ABBOTT LABORATORIES INC.
7.2. ACS BIOMARKER
7.3. AGILENT TECHNOLOGIES
7.4. ABCODIA LTD.
7.5. ADX NEUROSCIENCES NV
7.6. AVACTA GROUP PLC
7.7. AGENDIA
7.8. ASTELLAS PHARMA INC.
7.9. ANGLE BIOSCIENCES INC.
7.10. ALMAC GROUP
7.11. ALCEDIAG
7.12. BANYAN BIOMARKERS INC.
7.13. BCAL DIAGNOSTICS
7.14. BG MEDICINE INC.
7.15. BECKMAN COULTER, INC.
7.16. BECTON, DICKINSON AND COMPANY
7.17. BIOCLINICA
7.18. BIODESIX, INC.
7.19. BIOMÉRIEUX SA
7.20. BIO-RAD LABORATORIES INC.
7.21. BIOMARKER PHARMACEUTICALS CO., LTD
7.22. BIOMARKERBAY B. V.
7.23. BIOMARK DIAGNOSTICS INC.
7.24. BIOAGILYTIX LABS LLC
7.25. BIOMARKER LABS, INC.
7.26. BIOGAZELLE NV
7.27. BIOFLUIDICA INC.
7.28. BIOTHERA PHARMACEUTICALS INC.
7.29. CELLOMATICS BIOSCIENCES LTD.
7.30. CELERION
7.31. CISBIO BIOASSAYS
7.32. COVANCE INC.
7.33. CRITICAL DIAGNOSTICS
7.34. CROSSBETA BIOSCIENCE B.V.
7.35. CAMBRIDGE BIOMEDICAL INC.
7.36. CHARLES RIVER LABORATORIES, INC.,
7.37. DIAGENIC ASA
7.38. DENOVO BIOPHARMA LLC
7.39. DRUMETIX LABORATORIES, LLC
7.40. ENZO BIOCHEM INC.
7.41. EXTERNAUTICS SPA
7.42. F. HOFFMANN-LA ROCHE LTD
7.43. FRONTAGE LABS
7.44. FUTURE DIAGNOSTICS SOLUTIONS B.V.
7.45. GENENEWS LTD
7.46. GLYCOTECHNICA LTD.
7.47. HEALTHSPAN DIAGNOSTICS LLC
7.48. HOLOGIC INC.
7.49. HUMAN LONGEVITY, INC.
7.50. HVIVO SERVICES LIMITED
7.51. INSIGHT GENETICS INC.
7.52. ILLUMINA, INC.
7.53. ICON PLC
7.54. JANSSEN GLOBAL SERVICES,
7.55. LLCKCAS – BIOANALYTICAL & BIOMARKER SERVICES
7.56. LUMINEX CORPORATION
7.57. LIPOTYPE GMBH
7.58. MAPA BIOANALYSIS
7.59. MD BIOSCIENCES
7.60. MDNA LIFE SCIENCES INC.
7.61. MDXHEALTH
7.62. MERCK & CO., INC.
7.63. METABOLON INC.
7.64. METANOMICS HEALTH GMBH
7.65. MYRIAD GENETICS INC.
7.66. NEOGENOMICS, INC.
7.67. NANOSOMIX INC.
7.68. NANOSTRING TECHNOLOGIES, INC.
7.69. NOVARTIS AG
7.70. NORDIC BIOSCIENCE
7.71. PFIZER INC.
7.72. PERKINELMER INC.
7.73. PAMGENE INTERNATIONAL B.V.
7.74. PACIFIC BIOMARKERS INC.
7.75. PERSONALIS INC
7.76. PRECISION MEDICINE GROUP, INC.
7.77. PRECISION BIOMARKER RESOURCES INC.
7.78. QIAGEN N.V
7.79. QUANTERIX CORPORATION
7.80. Q2 SOLUTIONS
7.81. QUIBIM SL
7.82. RANDOX LABORATORIES LTD.
7.83. RESPONSE BIOMEDICAL CORPORATION
7.84. SIEMENS HEALTHINEERS
7.85. SIGNOSIS INC.
7.86. SIMPLICITYBIO SA
7.87. SGS SA
7.88. SYNEXA LIFE SCIENCES
7.89. STEMINA BIOMARKER DISCOVERY, INC.
7.90. THERMO FISHER SCIENTIFIC CORPORATION
7.91. TWAN BIOTECH COMPANY
7.92. TAMIRNA GMBH
7.93. VALIRX PLC
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
CHAPTER 2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHT & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1.1. UNITED STATES
2.3.1.2. EUROPEAN UNION
2.3.1.3. CHINA
2.3.1.4. INDIA
CHAPTER 3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. HIGH PREVALENCE OF CHRONIC DISEASES
3.1.2. RISING ADOPTION OF BIOMARKER FOR DIAGNOSTIC APPLICATIONS
3.1.3. HIGH GOVERNMENT FUNDING FOR CANCER RESEARCH AND CLINICAL TRIALS
3.1.4. INCREASING APPLICATION IN DRUG DISCOVERY AND DEVELOPMENT
3.2. RESTRAINT
3.2.1. HIGH INVESTMENTS COST AND LOW-COST BENEFIT RATIO
3.2.2. TECHNICAL ISSUE SUCH SAMPLE COLLECTION AND STORAGE
3.3. OPPORTUNITY
3.3.1. INTRODUCTION OF NEW TECHNOLOGIES SUCH AS DIGITAL BIOMARKER
3.3.2. RISING ADOPTION IN PERSONALIZED MEDICINE
CHAPTER 4. MARKET SEGMENTATION
4.1. GLOBAL BIOMARKER MARKET, BY TYPE
4.1.1. GENOMIC BIOMARKER
4.1.2. PROTEIN BIOMARKER
4.2. GLOBAL BIOMARKER MARKET, BY APPLICATION
4.2.1. DRUG DISCOVERY AND DEVELOPMENT
4.2.2. DIAGNOSTIC
4.2.3. PROGNOSTIC
4.2.4. PREDICTIVE
4.2.5. OTHERS (RISK ASSESSMENT)
4.3. GLOBAL BIOMARKER MARKET, BY DISEASE
4.3.1. CANCER BIOMARKER
4.3.2. CARDIAC BIOMARKER
4.3.3. RENAL BIOMARKER
4.3.4. CENTRAL NERVOUS SYSTEM DISEASE
4.3.5. OTHERS(NASH)
4.1. GLOBAL BIOMARKER MARKET, BY END USER
4.1.1. HOSPITALS
4.1.2. DIAGNOSTIC CENTRE
4.1.3. RESEARCH INSTITUTE
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1. KEY MARKET STRATEGIES
5.2. KEY COMPANY ANALYSIS
CHAPTER 6. REGIONAL ANALYSIS
6.1. NORTH AMERICAN
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. U.K
6.2.2. GERMANY
6.2.3. ITALY
6.2.4. SPAIN
6.2.5. FRANCE
6.2.6. ROE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. ROAPAC
6.4. REST OF THE WORLD
CHAPTER 7. COMPANY PROFILES
7.1. ABBOTT LABORATORIES INC.
7.2. ACS BIOMARKER
7.3. AGILENT TECHNOLOGIES
7.4. ABCODIA LTD.
7.5. ADX NEUROSCIENCES NV
7.6. AVACTA GROUP PLC
7.7. AGENDIA
7.8. ASTELLAS PHARMA INC.
7.9. ANGLE BIOSCIENCES INC.
7.10. ALMAC GROUP
7.11. ALCEDIAG
7.12. BANYAN BIOMARKERS INC.
7.13. BCAL DIAGNOSTICS
7.14. BG MEDICINE INC.
7.15. BECKMAN COULTER, INC.
7.16. BECTON, DICKINSON AND COMPANY
7.17. BIOCLINICA
7.18. BIODESIX, INC.
7.19. BIOMÉRIEUX SA
7.20. BIO-RAD LABORATORIES INC.
7.21. BIOMARKER PHARMACEUTICALS CO., LTD
7.22. BIOMARKERBAY B. V.
7.23. BIOMARK DIAGNOSTICS INC.
7.24. BIOAGILYTIX LABS LLC
7.25. BIOMARKER LABS, INC.
7.26. BIOGAZELLE NV
7.27. BIOFLUIDICA INC.
7.28. BIOTHERA PHARMACEUTICALS INC.
7.29. CELLOMATICS BIOSCIENCES LTD.
7.30. CELERION
7.31. CISBIO BIOASSAYS
7.32. COVANCE INC.
7.33. CRITICAL DIAGNOSTICS
7.34. CROSSBETA BIOSCIENCE B.V.
7.35. CAMBRIDGE BIOMEDICAL INC.
7.36. CHARLES RIVER LABORATORIES, INC.,
7.37. DIAGENIC ASA
7.38. DENOVO BIOPHARMA LLC
7.39. DRUMETIX LABORATORIES, LLC
7.40. ENZO BIOCHEM INC.
7.41. EXTERNAUTICS SPA
7.42. F. HOFFMANN-LA ROCHE LTD
7.43. FRONTAGE LABS
7.44. FUTURE DIAGNOSTICS SOLUTIONS B.V.
7.45. GENENEWS LTD
7.46. GLYCOTECHNICA LTD.
7.47. HEALTHSPAN DIAGNOSTICS LLC
7.48. HOLOGIC INC.
7.49. HUMAN LONGEVITY, INC.
7.50. HVIVO SERVICES LIMITED
7.51. INSIGHT GENETICS INC.
7.52. ILLUMINA, INC.
7.53. ICON PLC
7.54. JANSSEN GLOBAL SERVICES,
7.55. LLCKCAS – BIOANALYTICAL & BIOMARKER SERVICES
7.56. LUMINEX CORPORATION
7.57. LIPOTYPE GMBH
7.58. MAPA BIOANALYSIS
7.59. MD BIOSCIENCES
7.60. MDNA LIFE SCIENCES INC.
7.61. MDXHEALTH
7.62. MERCK & CO., INC.
7.63. METABOLON INC.
7.64. METANOMICS HEALTH GMBH
7.65. MYRIAD GENETICS INC.
7.66. NEOGENOMICS, INC.
7.67. NANOSOMIX INC.
7.68. NANOSTRING TECHNOLOGIES, INC.
7.69. NOVARTIS AG
7.70. NORDIC BIOSCIENCE
7.71. PFIZER INC.
7.72. PERKINELMER INC.
7.73. PAMGENE INTERNATIONAL B.V.
7.74. PACIFIC BIOMARKERS INC.
7.75. PERSONALIS INC
7.76. PRECISION MEDICINE GROUP, INC.
7.77. PRECISION BIOMARKER RESOURCES INC.
7.78. QIAGEN N.V
7.79. QUANTERIX CORPORATION
7.80. Q2 SOLUTIONS
7.81. QUIBIM SL
7.82. RANDOX LABORATORIES LTD.
7.83. RESPONSE BIOMEDICAL CORPORATION
7.84. SIEMENS HEALTHINEERS
7.85. SIGNOSIS INC.
7.86. SIMPLICITYBIO SA
7.87. SGS SA
7.88. SYNEXA LIFE SCIENCES
7.89. STEMINA BIOMARKER DISCOVERY, INC.
7.90. THERMO FISHER SCIENTIFIC CORPORATION
7.91. TWAN BIOTECH COMPANY
7.92. TAMIRNA GMBH
7.93. VALIRX PLC
LIST OF TABLES
Table 1 GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLIONS)
Table 2 GLOBAL GENOMIC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 3 GLOBAL PROTEIN BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 4 GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLIONS)
Table 5 GLOBAL DRUG DISCOVER AND DEVELOPMENT BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 6 GLOBAL DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY, 2017-2023 ($ MILLIONS)
Table 7 GLOBAL PROGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 8 GLOBAL PREDICTIVE BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 9 GLOBAL OTHERS BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 10 GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE, 2017-2023 ($ MILLIONS)
Table 11 GLOBAL CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 12 GLOBAL CARDIAC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 13 GLOBAL RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 14 GLOBAL CENTRE NERVOUS SYSTEM BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 15 GLOBAL OTHER BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 16 GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLIONS)
Table 17 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 18 GLOBAL DIAGNOSTIC CENTRE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 19 GLOBAL RESEARCH INSTITUTE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 20 GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2017-2023 ($ MILLION)
Table 21 NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
Table 22 NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
Table 23 NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
Table 24 NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE, 2017-2023 ($ MILLION)
Table 25 NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 26 EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
Table 27 EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
Table 28 EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
Table 29 EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE, 2017-2023 ($ MILLION)
Table 30 EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 31 APAC BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
Table 32 APAC BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
Table 33 APAC BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
Table 34 APAC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE, 2017-2023 ($ MILLION)
Table 35 APAC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 36 ROW BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
Table 37 ROW BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
Table 38 ROW BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE, 2017-2023 ($ MILLION)
Table 39 ROW BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 1 GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLIONS)
Table 2 GLOBAL GENOMIC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 3 GLOBAL PROTEIN BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 4 GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLIONS)
Table 5 GLOBAL DRUG DISCOVER AND DEVELOPMENT BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 6 GLOBAL DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY, 2017-2023 ($ MILLIONS)
Table 7 GLOBAL PROGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 8 GLOBAL PREDICTIVE BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 9 GLOBAL OTHERS BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 10 GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE, 2017-2023 ($ MILLIONS)
Table 11 GLOBAL CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 12 GLOBAL CARDIAC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 13 GLOBAL RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 14 GLOBAL CENTRE NERVOUS SYSTEM BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 15 GLOBAL OTHER BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 16 GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLIONS)
Table 17 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 18 GLOBAL DIAGNOSTIC CENTRE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 19 GLOBAL RESEARCH INSTITUTE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
Table 20 GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2017-2023 ($ MILLION)
Table 21 NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
Table 22 NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
Table 23 NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
Table 24 NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE, 2017-2023 ($ MILLION)
Table 25 NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 26 EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
Table 27 EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
Table 28 EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
Table 29 EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE, 2017-2023 ($ MILLION)
Table 30 EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 31 APAC BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
Table 32 APAC BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
Table 33 APAC BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
Table 34 APAC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE, 2017-2023 ($ MILLION)
Table 35 APAC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 36 ROW BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
Table 37 ROW BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
Table 38 ROW BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE, 2017-2023 ($ MILLION)
Table 39 ROW BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
LIST OF FIGURES
Figure 1 GLOBAL BIOMARKER MARKET SHARE BY TYPE, 2017 VS 2023 (%)
Figure 2 GLOBAL BIOMARKER MARKET SHARE BY APPLICATION, 2017 VS 2023 (%)
Figure 3 GLOBAL BIOMARKER MARKET SHARE BY DISEASE, 2017 VS 2023 (%)
Figure 4 GLOBAL BIOMARKER MARKET SHARE BY END USER, 2017 VS 2023 (%)
Figure 5 NORTH AMERICA BIOMARKER MARKET SHARE, 2017 VS 2023 (%)
Figure 6 US BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 7 CANADA BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 8 EUROPEAN BIOMARKER MARKET SHARE, 2017 VS 2023 (%)
Figure 9 UK BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 10 FRANCE BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 11 GERMANY BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 12 ITALY BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 13 SPAIN BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 14 ROE BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 15 ASIA PACIFIC BIOMARKER MARKET SHARE, 2017 VS 2023 (%)
Figure 16 INDIA BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 17 CHINA BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 18 JAPAN BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 19 ROAPAC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 20 REST OF THE WORLD BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 1 GLOBAL BIOMARKER MARKET SHARE BY TYPE, 2017 VS 2023 (%)
Figure 2 GLOBAL BIOMARKER MARKET SHARE BY APPLICATION, 2017 VS 2023 (%)
Figure 3 GLOBAL BIOMARKER MARKET SHARE BY DISEASE, 2017 VS 2023 (%)
Figure 4 GLOBAL BIOMARKER MARKET SHARE BY END USER, 2017 VS 2023 (%)
Figure 5 NORTH AMERICA BIOMARKER MARKET SHARE, 2017 VS 2023 (%)
Figure 6 US BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 7 CANADA BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 8 EUROPEAN BIOMARKER MARKET SHARE, 2017 VS 2023 (%)
Figure 9 UK BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 10 FRANCE BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 11 GERMANY BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 12 ITALY BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 13 SPAIN BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 14 ROE BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 15 ASIA PACIFIC BIOMARKER MARKET SHARE, 2017 VS 2023 (%)
Figure 16 INDIA BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 17 CHINA BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 18 JAPAN BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 19 ROAPAC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
Figure 20 REST OF THE WORLD BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
